

REMARKS

Currently claims 1-9, 12, and 14 are pending. Claims 10, 11, and 13 have been cancelled without prejudice to or disclaimer of the subject matter contained therein. Claims 1, 3-9, 12, and 14 have been amended to place them in form appropriate to US practice, and to reduce the filing fee by, *inter alia*, removing multiple dependency. Applicants have amended the specification for purposes of adding the priority information. In addition, the attached abstract has been placed on a separate sheet of paper in accordance with US practice.

It is believed that the current application is now in condition for examination. Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herein. However, should any other fees be deemed necessary to effect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,



Kathryn L. Coulter
Attorney for Applicant
Registration No. 45,889

Date: *July 26, 2006*
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-1467
Facsimile: 919-483-7977